News jeff 2018-05-31T11:46:02+00:00

News

TaiRx successfully raised 504 million NTD in capital.

2020/11/27 To enrich [...]

November 27th, 2020|News|

TaiRx ranked first in Taiwan for the most innovative pharmaceutical companies in the APAC region

2019/8/30 World-renowned professional [...]

August 30th, 2019|News|

TaiRx receives “Technology and Product or Technology Development is Successful and Marketable” recommendation from Industrial Development Bureau and starts CVM-1118 (Foslinanib) Phase II clinical trial in Taiwan and US.

2019/1/2 TaiRx, Inc. [...]

January 2nd, 2019|News|

TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics- Joint venture to focus on the Nodal protein, a previously untargeted and critical mediator of aggressive cancer progression and treatment resistance

2018/10/23 TaiRx, Inc [...]

October 23rd, 2018|News|

A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.

2018/4/15 TaiRx’s CVM-1118 [...]

April 15th, 2018|News|

Previous 123 Next